Medicinal product and method for treatment of conditions affecting neural stem cells or progenitor cells
CA 2352553 A1 · Owner: A+Science Ab · Inventors: Eriksson, Peter
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Use of a substance that upon administration will lead to increased concentrations of growth hormone, such as growth hormone a functionally , equivalent analogue thereof or a substance that will increase the release of endogenous growth hormone, for the production of a medicinal product for treatment of abnormal conditions affecting neural stem cells progenitor cells , and/or cells derived from neural stem cells or progenitor cells especially , conditions affecting the oligodendroglia astroglia, and/or neuronal cells. In , vitro and in vivo methods for inducing lineage determination propagating , and/or inducing or maintaining the genesis of neurons oligodendrocytes, astroglial cells from …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed November 25, 1999. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended November 25, 2019.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by November 25, 2021.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.